Celldex Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Celldex Therapeutics

04/05/2023 22:30

* Celldex Therapeutics Inc  CLDX.OQ  reported a quarterly
adjusted
loss of 62 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 63 cents per share.
    * Revenue rose 455.7% to $967.00 thousand from a year ago;
analysts expected $410.00 thousand. 
    * Celldex Therapeutics Inc's reported EPS for the quarter
was a
loss of 62 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Celldex Therapeutics Inc shares had fallen by 12.6% this
quarter and lost 29.4% so far this year.
    * The company reported a quarterly loss of $29.36 million.
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $67.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 09:29 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.63          -0.62          Beat
 Dec. 31 2022      -0.59          -0.56          Beat
 Sep. 30 2022      -0.58          -0.57          Beat
 Jun. 30 2022      -0.51          -0.59          Missed